I think they (Marc) should better inform about Immuteps priorities. First priority in my opinion is the P3 in NSLCC (huge TAM about 24 bn. USD). Other indications like HNSCC or breast Cancer have a much smaller tam. Because Liquidity is a shortage for Immutep they should clarify the market participants about their strategy. I do not believe that they can afford because of capabilities and liquidity more than phase 3 trial. It is a bit crazy that the share price reacted so weak to great results in cohort B in HNSCC. So better communication to us shareholders is necessary.
Media, page-83
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.010(3.51%) |
Mkt cap ! $400.0M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.3¢ | 27.0¢ | $1.034M | 3.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 98156 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 85523 | 9 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |